Moreover, sole pharmacological inhibition of EGFR by the tyrosine kinase inhibitor erlotinib displayed no activity in 2D clonogenic survival assays, nor in 3D GBM spheroids [63]. This evidence concerns the gene EGFR and glioblastoma.